NCT00453349View on ClinicalTrials.gov

A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Pelvic Inflammatory Disease
Interventions
DRUG

Moxifloxacin (Avelox, BAY12-8039)

Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days

DRUG

Levofloxacin & Metronidazole

Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days

Trial Locations (13)

402

Taizung

10002

Taipei

10700

Bangkok

100034

Beijing

100083

Beijing

110004

Shenyang

133792

Seoul

200011

Shanghai

400010

Chongqing

610041

Chengdu

Unknown

Jakarta

Karachi

Manila

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00453349 - A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease | Biotech Hunter | Biotech Hunter